Objectives: To describe 5-and 10-year rates of metastasis-free survival (MFS) stratified by Gleason score (GS) and prostate-specific antigen doubling time (PSADT) for patients receiving salvage radiation therapy (SRT) after biochemical recurrence (BR) postradical prostatectomy (RP).
has the potential for cure in a subset of patients with rising PSA after RP, even in those with high-risk features (such as high Gleason score or short PSA doubling time), although some have argued against the use of SRT in this group for fear of toxicity, 4 which is likely over emphasized. 5 No prospective trials comparing SRT to other treatments have been performed, but 2 large retrospective reviews have demonstrated improved prostate cancer-specific survival with SRT for patients experiencing BR post-RP. 6, 7 Recently, Antonarakis et al 1 reported the 5-and 10-year rates of metastasis-free survival (MFS) for 450 prostate cancer patients experiencing BR after treatment with RP, stratified by Gleason score (GS) and prostate-specific antigen doubling time (PSADT). The 450 patients represented a unique cohort. In that, any patient receiving additional treatment before the detection of metastatic disease was excluded from the analysis. Thus, the study claims to present the "natural history" of development of metastases for men who experience BR after RP. Nevertheless, this was a highly selected group from an initial cohort of 1973 patients with BR post-RP. Only 450 patients were included in the analysis as 798 were given some form of adjuvant/salvage therapy, 533 were lost to follow-up or were lacking necessary data, and 192 did not have sufficient PSA data to calculate PSADT. These results, therefore, likely reflect a unique group of patients whose clinical characteristics were consistent with observation and may not reflect the outcome for all patients with BR after RP. We hypothesized that MFS survival would be improved in a cohort of men who received SRT without other concurrent or adjuvant therapy after BR post-RP and similarly, did not receive additional salvage therapy until after developing metastases, thereby assessing the impact of SRT alone on MFS. Thus, we sought to assess MFS as a function of GS and PSADT in a cohort of patients treated with SRT at a single institution and to calculate 5-and 10-year rates of MFS stratified by GS and PSADT and compare these to the results reported by Antonarakis et al. 1 
METHODS AND MATERIALS

Patient Selection
Through an institutional review board-approved retrospective analysis, data for 575 patients who received SRT for BR post-RP were reviewed. Sufficient data to calculate pre-SRT PSADT was available for 277 patients. Of the 277 patients with known PSADTs, 41 received either concurrent or adjuvant ADT and were excluded, limiting our analysis to patients treated solely with SRT. This resulted in a cohort of 236 patients. Eighty nine patients (38%) received salvage ADT after SRT. Of the 83, 68 of these patients received salvage ADT before the development of metastasis and were excluded from the analysis of 5-and 10-year rates of MFS. Any patient receiving RT for a persistently elevated post-RP PSA and any patient receiving RT for BR post-RP were considered as having received SRT. All patients received SRT between 1986 and 2010.
Treatment and Follow-up
SRT was delivered using either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy. Treatment fields were usually limited to the prostatic fossa, with only 8.5% of patients additionally receiving treatment to a pelvic field. Patients considered as low, intermediate, and high risk as determined by pre-SRT PSA, typically received 64.8 Gy (PSA < 0.4), 68.4 Gy (PSA 0.4 to 1.0), and 70.2 Gy (PSA > 1.0), respectively, to the prostatic fossa. Pelvic fields were usually treated with 45 Gy. Typical practice was to see patients in follow-up 3 to 4 times per year during the first 2 years after treatment, biannually for the next 3 years, and then annually thereafter.
Endpoints
The primary endpoint for this analysis was MFS. MFS was defined as the absence of any clinical, pathologic, or radiographic evidence of metastases and was measured starting from initial BR after RP. BR was defined as a rise in PSA of 0.2 ng/mL above the post-SRT nadir followed by a second higher value 8 or any PSA value of > 0.5 ng/mL above the post-SRT nadir.
Statistical Analysis
Continuous variables were compared using the one-way analysis of variance (ANOVA), and categorical variables were compared using the w 2 test. The Kaplan-Meier methods and log-rank analysis were used to calculate MFS and other survival rates. PSADT was calculated using the previously described methods. 2 Supersensitive PSA values were not used to calculate PSADTs. All statistical analysis was performed using MedCalc (v12.3.0.0; MedCalc Software, Mariakerke, Belgium).
RESULTS
Patient Characteristics
A total of 236 men treated with SRT, who did not receive concurrent or adjuvant ADT, and had sufficient PSA data available to calculate PSADTs were retrospectively reviewed. 1 ECE indicates extra-capsular extension; GS, Gleason score; LNI, lymph node involvement; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; RP, radical prostatectomy; SM, surgical margin; SRT, salvage radiation therapy; SVI, seminal vesicle invasion; UMHS, University of Michigan Health System;WPRT, whole-pelvic radiation therapy.
Median time from RP to BR was 2.3 years (interquartile range [IQR] 1.0 to 3.9 y), median time from RP to SRT was 3.4 (IQR 1.6 to 5.6 y) years, and median time from BR to SRT was 9 months (IQR 4 to 18 mo). Median follow-up post-SRT was 7.1 (IQR 4.2 to 9.5 y) years. Mean age at RP was 60 years, and 64 years at initiation of SRT. Median pre-RP PSA was 7.8 ng/mL (IQR 5.4 to 12.9 ng/mL), and median pre-SRT PSA was 0.6 ng/ mL (IQR 0.4 to 1.1 ng/mL). The majority of patients had pathologic T3 or T4 disease (56.4%).
Patient characteristics for the entire cohort and those for men who did and did not develop metastases can be found in Table 1 . Moreover, Table 1 include the patient characteristics from the analysis by Antonarakis et al 1 for comparison. In the SRT group, men who developed metastases had a higher incidence of pathologic T3 and T4 disease than those who did not (73.5% vs. 50.4%, respectively; P = 0.02) and had an increased prevalence of GS 8 to 10 (33.9% vs. 12.0%, respectively; P < 0.0001). They were also more likely to have ECE (59.3% vs. 41.0%, respectively; P = 0.02), SVI (22.0% vs. 6.4%, respectively; P = 0.002), and had a higher incidence of PSADTs < 9 months (72.8% vs. 48.0%, respectively; P = 0.004).
Biochemical Recurrence and Salvage ADT Use
Both GS and PSADT predicted biochemical recurrencefree survival post-SRT (both P < 0.001), as shown in Figure 1A and B, respectively. Patients with GS 8 to 10 were at higher risk for BR than patients with GS 7 who were at higher risk for BR than GS 2 to 6 patients. PSADT similarly stratified patients' risk for BR. Although patients with GS 8 to 10 and PSADT < 3 months were most likely to experience BR, at 5 years after SRT, approximately 20% of patients with GS 8 to 10 or PSADT < 3 months had yet to experience BR. Time to initiation of salvage ADT from BR post-RP was also determined for patients as a function of GS and PSADT. GS and PSADT stratified patients by their likelihood of receiving salvage ADT after BR (both P < 0.001, Figs. 2A, B) . As seen in Figure 1 , although approximately 20% of high-risk patients (GS 8 to 10 or PSADT < 3 mo) had not experienced BR after SRT, approximately 40% of these high-risk patients had yet to initiate salvage ADT at 5 years after BR post-RP, as seen in Figure 2 .
MFS
As of last follow-up, 59 men (25%) had developed metastasis. Any patient receiving salvage ADT before developing metastases was excluded from MFS analysis (n = 65). Median MFS for the remaining 171 patients, which was calculated from initial BR post-RP to the development of metastasis or time of censoring, was 7. PSADT <3 months PSADT 3-9 months PSADT 9-15 months PSADT >15 months not be determined using the Kaplan-Meier methods as the survival curve reached an asymptote before crossing the 50% survival probability. MFS was determined as a function of GS and PSADT using the Kaplan-Meier methods. Stratification by GS resulted in low-risk, intermediate-risk, and high-risk groups for developing metastases (P < 0.0001; Fig. 3A) . Patients with GS 7 were at higher risk for developing metastases than patients with GS 2 to 6 (HR:6.3; 95% confidence interval [CI], 3.1-13.1; P = 0.003). Similarly, patients with GS 8 to 10 were at higher risk than those with GS 7 for DM (HR:2.2; 95% CI, 1.1-4.4; P = 0.01). MFS was next analyzed by PSADT as a categorical variable (< 3, 3 to 9, 9 to 15, and >15 mo). This stratification of PSADT also predicted MFS (P = 0.001; Fig. 3B ). Patients with a PSADT of 9 to 15 months did not have different rates of MFS compared with those with a PSADT > 15 months (P = 0.4). Likewise, patients with a PSADT < 3 months had similar MFS compared with those with a PSADT of 3 to 6 months (P = 0.4). However, patients with a PSADT < 9 months were at a higher risk of DM than those with a PSADT > 9 months (HR:3.4; 95% CI, 2.0-5.7; P < 0.0001). Next, 5-and 10-year rates for MFS were determined for GS 2 to 6, 7, and 8 to 10, and PSADT < 3, 3 to 9, 9 to 15, and >15 months (Figs. 4A, B) . The 5-and 10-year MFS rates from the Antonarakis analysis are included in Figures 4A and B for comparison. 1 Each decrease in GS resulted in an increase in MFS at 5 and 10 years. The 5-and 10-year MFS for GS 8 to 10 were 62% and 50%, respectively, compared with 94% at both 5 and 10 years for GS 2 to 6. In general, each decrease in PSADT grouping resulted in decreased MFS. The 5-and 10-year MFS for PSADT < 3 months were 70% and 61%, respectively, compared with 100% and 90% at 5 and 10 years, respectively, for PSADT >15 months.
DISCUSSION
The primary objectives of this analysis was to report 5-and 10-year MFS rates in our cohort after SRT and to compare these rates to the MFS rates after BR post-RP presented by Antonarakis et al. 1 Comparison of outcomes across analyses of separate cohorts is inherently difficult; however, there are many similarities between the 2 groups. Both cohorts received treatment for prostate cancer at tertiary medical centers over similar time periods (1980 to 2010), increasing the likelihood of similar patient populations. Further supporting this notion is the fact that baseline characteristics between the 2 cohorts were rather similar ( Table 1 ). The median time from surgery to BR was similar between the 2 groups (3.1 for Antonarakis and colleagues vs. 2.3 y for the SRT cohort). Finally, overall follow-up after BR was 4 years in the Antonarakis analysis and 7 years after receiving SRT in our analysis.
The most notable difference was in the prevalence of LNI. Patients in our cohort with positive lymph nodes were not routinely sent for SRT or were apt to receive RT with ADT, given the results of the randomized trial by Messing and colleagues supporting ADT use in the setting of node-positive cancer after RP and the results from RTOG 8531, which included a subgroup of men with positive lymph nodes. 9, 10 The difference in prevalence of lymph nodes could explain some of the differences in outcomes between these cohorts. Nevertheless, it does not lessen the fact that a significant minority of men after receiving SRT can have long periods free of metastasis, which warrants the use of SRT even in higher risk groups (such as those with GS 8 to 10 or with short PSADTs). An additional difference between cohorts, which is difficult to control for, is the fact that the Antonarakis cohort is a highly selected group of patients who experienced BR but did not receive salvage therapy after RP, and ours is a highly selected group of patients who all received SRT after BR post-RP.
We have demonstrated that MFS rates after SRT alone for post-RP BR are low and when compared with recently published results from Antonarakis and colleagues, suggest that SRT may reduce MFS rates as compared with withholding SRT altogether. Five-and 10-year MFS rates in our SRT cohort were improved as compared with those from the analysis by Antonarakis and colleagues (Fig. 4A, B) . For every grouping of GS and PSADT, patients from our cohort had an equivalent or greater MFS at 5 and 10 years, with the largest difference in MFS occurring in patients with highest GS or shortest PSADT. For instance, 5-and 10-year MFS rates for patients in our cohort with GS 8 to 10 were 62% and 50%, respectively, compared with 43% and 19%, respectively, in the Antonarakis cohort. Likewise, the 5-year MFS rate for patients in our cohort with PSADT < 3 months was 70% compared with 5% in the Antonarakis cohort and for patients with a PSADT of 3 to 9 months, 5-and 10-year MFS rates were 81% and 60%, respectively, in our cohort, compared with 27% and 7%, respectively, in the Antonarakis cohort. For patients receiving SRT after BR post-RP, development of metastasis was highly correlated to the presence of adverse pathologic features and clinically more aggressive disease as represented by a shorter PSADT. Advanced postprostatectomy pathologic stage, higher GS, and the presence of SVI and ECE were all more common in men who developed metastases after receiving SRT than in those who did not. Patients with aggressive pathologic findings post-RP are more likely to experience metastasis and poor outcomes compared with patients with less aggressive disease; however, these same patients with aggressive disease have the potential to obtain the greatest benefit from SRT at the time of BR. Many have incorrectly proposed that SRT be reserved for patients with less aggressive disease or for whom predictive nomograms calculate a high likelihood of a durable biochemical response to treatment. 4, [11] [12] [13] [14] Despite the fact that men with GS 8 to 10 or a PSADT < 3 months are thought to be at high risk of recurrence after receiving SRT, our data show that approximately 20% of these patients had not experienced a post-SRT BR by 5 years. Furthermore, 40% of these patients were free of additional salvage therapy, 5 years after BR post-RP, and greater than one third had yet to initiate any additional salvage therapy at 10 years. Although it is true that high-risk patient populations are overall less likely to obtain long-term responses from SRT, a subset of this population comprises the group that gains the greatest benefit from SRT, that is, those with earlyidentified aggressive local recurrences. SRT can potentially provide a curative treatment for patients with aggressive local disease who are at a high risk for metastasis and death. This concept is supported by extrapolation of the results of the present analysis in comparison with the results of Antonarakis and colleagues, where the greatest magnitude difference in 5-and 10-year rates of MFS was for patients with GS 8 to 10 and a PSADT < 9 months. Further evidence that high-risk patients have the most to benefit from SRT comes from analyses by Trock and colleagues and Cotter and colleagues. 6, 7 Both authors found that SRT provided a prostate cancerspecific survival for patients with a PSADT < 6 months. Cotter et al 6 also demonstrated a survival benefit for those with a PSADT > 6 months but found that the adjusted benefit of SRT was greater for those with a PSADT < 6 months. Thus, although patients with clinically aggressive prostate cancer are at greatest risk for metastases and poor clinical outcomes after SRT, many of these patients may gain an immense benefit from SRT, and this treatment should not be withheld solely based upon the presence of these adverse features.
The present analysis has several limitations. First, the retrospective nature allows for the presence of unknown and unmeasured confounders. Secondly, selection bias exists as our patient population is highly selected for patients treated solely with SRT after BR post-RP. Selection bias also exists in the analysis by Antonarakis and colleagues, and their cohort represents that the 23% of their patients who experienced BR but did not receive any form of adjuvant or salvage therapy and had all the data available for analysis. Intuitively, one may expect a trend towards more aggressive disease in the patients who received SRT as compared with those who were selected for observation alone. However, the similarity in baseline characteristics between the 2 cohorts does warrant the current comparison. Nevertheless, unknown factors likely existed that resulted in patients receiving SRT or being observed and may confound the comparison herein. Lastly, only 267 out of 575 patients had sufficient data to be included in this analysis; however, there was no statistically significant difference in rates of BF or MFS between the patients included or excluded from the present analysis (both P > 0.2).
Despite an apparent role for SRT, there were still relatively poor outcomes in the patients with the highest risk features either with observation or with SRT. Both the Messing study and RTOG 8531 would support the use of a life-long ADT in men with node-positive prostate cancer either without (Messing) or with RT (RTOG 8531) in the adjuvant setting before observed BF. 9, 10 In addition, findings from RTOG 9601 were recently reported, where in a high-risk group of men receiving SRT after RP (with a median PSA of 2.0), there was a 25% improvement in 5-year freedom from BF with ADT and a 7% improvement in MFS, with the magnitude of this benefit appearing greater with increasing Gleason score. 15 Both the RADICALS 16 trial in Great Britain and the RTOG 0534 (SPPORT) trial are currently evaluating the role of short-term ADT concurrent with SRT and will more fully answer this question. Finally, the role of pelvic RT in this setting (particularly with positive lymph nodes) is unclear at present. However, this is also being prospectively evaluated in the RTOG 0534 (SPPORT) trial.
In conclusion, the decision to initiate SRT after BR post-RP should be made between the physician and the patient. Our results suggest that a conversation discussing the option of SRT is appropriate for many patients who experience BR post-RP. Patients should not be excluded from receiving SRT based solely on aggressive clinical features, such as a high GS or short PSADT, as these patients have the potential to gain an immense benefit from SRT. Patients with less-aggressive disease should also be offered the option of SRT as they often obtain long and durable responses to SRT. Until improved means of detecting micrometastatic disease exist, SRT should be offered to most patients experiencing BR post-RP, regardless of disease risk status, as patients with clinically aggressive and indolent disease have the potential to benefit from SRT.
